MannKind Corporation (MNKD) Could Sink 90%: TourbillionMark Melin
Hedge fund Tourbillion Capital Partners doesn’t like health care stock MannKind Corporation (NASDAQ:MNKD) and is betting it could tumble by as much as 90 percent, CNBC’s Lawrence Delevingne is reporting.
MannKind's Afrezza will fail due to potential customer backlash
Tourbillion thinks MannKind Corporation (NASDAQ:MNKD)’s lead diabetes treatment product, Afrezza, which recently won FDA approval, will fail . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible